John Anderson, MD
Internal Medicine · Nashville, TNNPI 1003801788
Payments from drug & device makers
Across 2,353 payments — averaging $625.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$574K
- Sanofi-aventis U.S. LLC$236K
- Novo Nordisk$226K
- AstraZeneca$136K
- Eli Lilly$76K
- Corcept Therapeutics$43K
- plus $180K from 42 others
Across 11 payments — averaging $850.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$9K
What the payments were for
- Consulting fees$313,69521%
- Speaking & faculty fees$1,046,30771%
- Travel & lodging$77,4985%
- Food & beverage$33,5712%
- Education$660%
- Gifts$590%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$276,284
- TRULICITY$252,115
- FARXIGA$100,796
- TOUJEO$89,374
- SOLIQUA 100/33$82,469
- RYBELSUS$75,078
- Ozempic$54,755
- Korlym$41,673
- JARDIANCE$37,300
- INVOKANA$36,828
- TZIELD$35,091
- Kerendia$33,555
- FREESTYLE LIBRE 3$17,543
- Victoza$14,515
- BYDUREON$13,292
- Tresiba$13,279
- FreeStyle Libre Pro$11,712
- Omnipod$6,075
- LANTUS$5,540
- FreeStyle Libre$4,391
How this compares
$1,471,226 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 153 | $170,664 |
| JardianceEmpagliflozin | 137 | $151,331 |
| TrulicityDulaglutide | 84 | $113,761 |
| FarxigaDapagliflozin Propanediol | 91 | $100,708 |
| OzempicSemaglutide | 73 | $89,575 |
| EliquisApixaban | 63 | $72,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $68,323 |
| XareltoRivaroxaban | 36 | $49,568 |
| MyrbetriqMirabegron | 27 | $29,732 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $24,687 |
| LinzessLinaclotide | 26 | $19,781 |
| JanuviaSitagliptin Phosphate | 27 | $18,996 |
| EntrestoSacubitril/Valsartan | 16 | $18,318 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $14,333 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $10,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $574,143 | $288,434250 claims |
| Boehringer IngelheimJardiance | $18,648 | $151,331137 claims |
| AstraZenecaFarxiga, Symbicort | $135,949 | $107,313103 claims |
| Novo NordiskOzempic | $226,310 | $89,57573 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,140 | $79,31384 claims |
| PfizerEliquis, Premarin | $1,396 | $77,71783 claims |
| Johnson & JohnsonXarelto | $37,653 | $49,56836 claims |
| Astellas Pharma US IncMyrbetriq | $3,129 | $29,73227 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $236,156 | $24,68714 claims |
| AbbVieLinzess, Synthroid | $715 | $22,92287 claims |
| MerckJanuvia | $188 | $18,99627 claims |
| NovartisEntresto | $4,373 | $18,31816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- Nancy DavisNashville$985K
- Wayne RileyNashville$536K
- Paul FerrellNashville$413K
- Cyndya Shibao MiyasatoNashville$364K
- Hilary TindleNashville$337K
- Harvey BowlesNashville$203K
- Jay MontgomeryNashville$174K
- Temidayo AbeNashville$113K
- Nader BahriNashville$105K
- Harvey MurffNashville$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.